Shares of Asensus Surgical Inc. (ASXC) have gained 5.69% to trade at $2.60 at the start of the trading on Wednesday. The Asensus stock decreased -5.02% to $2.46 during the last trading session. There was a trading volume of 3.96 million shares of ASXC stock, which is lower than the average daily volume published for the last 50 days of 11.12 million shares.
During the last five days, shares of the ASXC stock are down 13.68%; however, over the last month, they are down 23.60%. Since the beginning of the year, ASXC stock has risen 293.60 percent. Following an FDA submission, ASXC stock has been rising today.
What has ASXC filed?
By unlocking clinical intelligence, Asensus enables consistently superior surgical outcomes and a new standard of care through a digital interface between surgeon and patient. With the Senhance Surgical System powered by the Intelligent Surgical Unit (ISU), ASXC builds upon the foundation of digital laparoscopy to increase surgeon control and reduce surgical variability.
ASXC intends to address the current clinical, cognitive, and economic obstacles driving surgical outcomes and value-based healthcare outcomes holistically by integrating machine vision, artificial intelligence, and deep learning capabilities throughout the surgical experience.
Today, Asensus announced it had filed a 510(k) with the U.S. Food and Drug Administration (FDA) to expand the capabilities of its previously approved Intelligent Surgical Unit (ISU).
- In addition to ASXC’s Senhance Surgical System, the ISU is employed on the Senhance for digital laparoscopy.
- Enhancing ASXC’s augmented intelligence capabilities is the next key to increasing its competitiveness in digital surgery.
- ASXC will soon be adding new capabilities to the Senhance Surgical System.
- With these new features, surgeons would be able to perform surgery in a more consistent manner and have access to new planning tools not available before in digital and robotic surgery
- In its current state, the ISU offers the ability to control the camera from within a surgical field through machine vision, recognizing certain objects and locations and allowing the surgeon to change the field of view using instruments.
- With the new features of ASXC, users will have access to more advanced features that will gather real-time data during surgeries based on the anatomical structures of the surgical site.
What does ASXC’s new functionality entail?
As a result of this submission, Asensus (ASXC) will continue to lead augmented intelligence and machine vision in surgery in the future. In addition to surgical planning and decision support, the new capabilities will enhance teaching capabilities for ASXC.
